An interventional study of Neurological assessment and Ophthalmological assessment in Spinocerebellar Ataxia, sponsored by University Hospital, Montpellier. Recruiting at 1 site in France. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-11-20.
Sponsored by University Hospital, Montpellier · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Spinocerebellar Ataxias with a site in France — 5 open to participants now, 7 under way, none of them phase 3. Spinocerebellar Ataxias · France.
Among the 13 studies in Spinocerebellar Ataxias with a site in France, this one is one of 2 that started in 2025, is one of 3 with no phase, and was the 12th registered.
95 studies on the registry are indexed under Spinocerebellar Ataxias; 25 are open to participants now.
Browse Spinocerebellar Ataxias studies →5 of the 13 studies in Spinocerebellar Ataxias with a site in France are open now. Recruiting first, the newest first:
University Hospital, Angers · Sites in France
Ages 18–100 · Healthy volunteers
Vico Therapeutics B. V. · Sites in France, Denmark, Germany and 3 more countries
Ages 25–60
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 7+ · Healthy volunteers
Ataxia Study Group · Sites in France, Austria, Belgium and 7 more countries
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 16 Spinocerebellar Ataxias studies recruiting now, 8 (50%) set no upper age limit and 3 (19%) stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 1 · Phase 3 1
First in 2005; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is above the median of 29 across 61 interventional studies indexed under Spinocerebellar Ataxias.
Median enrollment 60 across the 6 interventional studies, 102 across the 7 observational. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 13 have an industry lead sponsor. The 8 most frequent:
University Hospital, Montpellier is the lead sponsor of 1,264 studies on the registry; 226 are open to participants now.
University Hospital, Montpellier has 2 studies filed under Spinocerebellar Ataxias — fewer than ten, so there is no comparison to draw.
2 of the studies in Spinocerebellar Ataxias with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06672445Arrowhead PharmaceuticalsStudy of ARO-ATXN2 Injection in Adults With Spinocerebellar Ataxia Type 2 | 2026-12 |
| NCT07019558University Hospital, MontpellierOphthalmological Disorders in Dominant Spinal-cerebellar Ataxias | 2027-10 |
Add all 2 to your calendar (.ics) → With an account.
Among the 13 studies in Spinocerebellar Ataxias with a site in France, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Spinocerebellar ataxias (SCA) are rare genetic neurological disorders. The most common forms are SCA1, SCA2 and SCA3. Another more recently identified cause of ataxia is SCA27B.
These are progressive, incapacitating pathologies, with adult onset (generally between 30 and 60 years of age) and progressive involvement. They are characterized by gait instability (ataxia), coordination disorders (dysmetria) and speech disorders (dysarthria). A complex disorder may also be present, with impaired ocular motility, double vision (diplopia) and difficulties with eye movements (ophthalmoplegia).
In clinical practice, investigators have observed patients with advanced forms of SCA1 or SCA3 reporting a progressive decline in visual acuity. Other recent scientific observations confirm the possible presence of additional ophthalmological damage to the retina or optic nerve in SCA1, SCA2 and SCA3 pathologies.
This study is a cross-sectional study, including subjects with SCA1, SCA2 and SCA3 at different stages of the disease, including the presymptomatic stage, with a complete and systematic study of visual damage.
The same study will be applied to subjects with SCA27B in order to study the presence or absence of visual impairment, and possibly compare it with those of patients with polyglutamine-expanded SCA.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Study-specific criteria:
General exclusion criteria relating to regulations:
* Symptomatic subjects with SCA1, SCA2 or SCA3, symptomatic subjects with SCA27B. * Presymptomatic subjects carrying the mutation for SCA1, SCA2 and SCA3.
Other: Neurological assessment · Diagnostic Test: Ophthalmological assessment
Collect retrospective and current clinical data and assess motor impairment
Ophthalmological assessment of possible optic nerve or retinal damage.
Percentage (%) of patients with SCA1, SCA2, or SCA3 showing abnormalities for each ophthalmological examination performed.
* Visual Acuity Assessment: Significant reduction in visual acuity (\<5/10) unexplained by other causes (such as age or other diseases). * Color Vision: Normal or pathological, with description of the axis * Fundus Examination: Normal or pathological (presence of retinopathy or optic nerve atrophy). * Optical Coherence Tomography (OCT): Evaluation of retinal nerve fiber layer (RNFL) and macular thickness (at 3 mm and 6 mm from the center), including retinal thickness, ganglion cell layer thickness, and the status of the ellipsoid zone. These thickness measurements are quantified according to age-adjusted normative database values. * Visual Evoked Potentials (VEP): Normal or pathological; if pathological, characterized by prolonged conduction times and/or reduced amplitude. * Electroretinogram (ERG): Normal or pathological; if pathological, defined by alteration (\>2 standard deviations) in the amplitude or latency of a- or b-waves under photopic or scotopic conditions
Time frame: 1 day
Percentage (%) of subjects showing abnormalities for each ophthalmological examination performed
Percentage (%) of subjects showing abnormalities for each ophthalmological examination performed to compare disorder across the three different types of SCA.
Time frame: 1 day
Severity of clinical impairment assessed by the SARA score (Scale for the Assessment and Rating of Ataxia) and the associated disability scale.
Severity of clinical impairment assessed by the SARA score (Scale for the Assessment and Rating of Ataxia) and the associated disability scale to correlate ophthalmological abnormalities. The SARA is a tool for assessing ataxia. It has eight categories with accumulative score ranging from 0 (no ataxia) to 40 (most severe ataxia) where higher scores indicate worse clinical impairment.
Time frame: 1 day
Disease duration: number of years between the estimated symptom onset and the time of study inclusion.
Disease duration: number of years between the estimated symptom onset and the time of study inclusion to assess whether this disorder is early and already present at a presymptomatic stage
Time frame: Day 1
Percentage (%) of patients with SCA27B showing abnormalities for each ophthalmological examination performed.
* Visual Acuity Assessment: Significant reduction in visual acuity (\<5/10) unexplained by other causes (such as age or other diseases). * Color Vision: Normal or pathological, with description of the axis * Fundus Examination: Normal or pathological (presence of retinopathy or optic nerve atrophy). * Optical Coherence Tomography (OCT): Evaluation of retinal nerve fiber layer (RNFL) and macular thickness (at 3 mm and 6 mm from the center), including retinal thickness, ganglion cell layer thickness, and the status of the ellipsoid zone. These thickness measurements are quantified according to age-adjusted normative database values. * Visual Evoked Potentials (VEP): Normal or pathological; if pathological, characterized by prolonged conduction times and/or reduced amplitude. * Electroretinogram (ERG): Normal or pathological; if pathological, defined by alteration (\>2 standard deviations) in the amplitude or latency of a- or b-waves under photopic or scotopic conditions
Time frame: 1 day
Plan to share: Undecided
No publications or documents are linked to this record.
Started Oct 2025 (actual). Primary completion is estimated for Oct 2027, 24 months after the start.
Of 28 interventional studies with no phase under Spinocerebellar Ataxias, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 30. This study's planned 24 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Montpellier →